Defining patient populations that will respond to a specific therapy is obviously important, and upon completion of trials a retrospective analysis is often performed to identify factors that may predict response.  However, recent research finds that a new tool in biomarker discovery may be inferred through the analysis of Kaplan-Meier (KM) curves for time-to-event data from clinical trials. (Cancer Therapy Advisor)